Keywords: Eli Lilly, Alnara Pharma, M&A, Liprotamase, Pancreatic enzyme replacement therapy
Eli Lilly to acquire Alnara Pharma, gaining access pancreatic enzyme replacement therapy now under FDA review
Article | 05 July 2010
US drug major Eli Lilly has signed a definitive agreement to acquire Alnara Pharmaceuticals, a privately held biotechnology company developing ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- New study shows UCB's Neupro reduces NSBP in RLS patient
- Encouraging results with Sangamo's SB-728-T in HIV treatment
- Sanofi prepares for regulatory filing of MF candidate on positive JAKARTA study results
